Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: An imaging, biochemical and molecular modeling study

Palma Dileo, Sabrina Pricl, Elena Tamborini, Tiziana Negri, Silvia Stacchiotti, Alessandro Gronchi, Paola Posocco, Erik Laurini, Paola Coco, Elena Fumagalli, Paolo G. Casali, Silvana Pilotti

Research output: Contribution to journalArticle

Abstract

Beside the well known "in vivo" and "in vitro" Imatinib resistant D842V mutation in PDGFRA receptor, very few are the information concerning the "in vivo" Imatinib activity with respect to the other PDGFRA mutations for which only "in vitro" data are available. Two patients carrying PDGFRA mutations in exons 18 (involving residues DIMH842-845) and 12 (V561D), respectively, were treated with Imatinib at a dose of 400 mg/day. According to Response Evaluation Criteria in Solid Tumors criteria, after a median treatment of 7 months both patients showed clinical partial response, and underwent surgery of the minimal residual disease. Tumor response was confirmed pathologically. In both patients, analyses of PDGFRA performed on pre- and/or post-treatment material were compared to affinity data of the mutated receptor towards the inhibitor. Molecular modeling evidence was found to be consistent with sensitivity of mutated PDGFRA receptors to Imatinib. Thus, the "in vivo" evidence that these two mutations of PDGFRA are sensitive to Imatinib was confirmed by a multidimensional approach comprising "in silico" experiments that, in association to molecular and biochemical analyses, constitutes a powerful tool to predict Imatinib sensitivity, clinically beneficial in the treatment of these tumors with molecularly targeted therapies.

Original languageEnglish
Pages (from-to)983-990
Number of pages8
JournalInternational Journal of Cancer
Volume128
Issue number4
DOIs
Publication statusPublished - Feb 15 2011

Fingerprint

Molecular Imaging
Mutation
Residual Neoplasm
Therapeutics
Computer Simulation
Imatinib Mesylate
Exons
Neoplasms

Keywords

  • GIST
  • Imatinib-mesylate
  • PDGFRA
  • targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations : An imaging, biochemical and molecular modeling study. / Dileo, Palma; Pricl, Sabrina; Tamborini, Elena; Negri, Tiziana; Stacchiotti, Silvia; Gronchi, Alessandro; Posocco, Paola; Laurini, Erik; Coco, Paola; Fumagalli, Elena; Casali, Paolo G.; Pilotti, Silvana.

In: International Journal of Cancer, Vol. 128, No. 4, 15.02.2011, p. 983-990.

Research output: Contribution to journalArticle

@article{1cc3a91135f84a5eb89982a3a710e192,
title = "Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: An imaging, biochemical and molecular modeling study",
abstract = "Beside the well known {"}in vivo{"} and {"}in vitro{"} Imatinib resistant D842V mutation in PDGFRA receptor, very few are the information concerning the {"}in vivo{"} Imatinib activity with respect to the other PDGFRA mutations for which only {"}in vitro{"} data are available. Two patients carrying PDGFRA mutations in exons 18 (involving residues DIMH842-845) and 12 (V561D), respectively, were treated with Imatinib at a dose of 400 mg/day. According to Response Evaluation Criteria in Solid Tumors criteria, after a median treatment of 7 months both patients showed clinical partial response, and underwent surgery of the minimal residual disease. Tumor response was confirmed pathologically. In both patients, analyses of PDGFRA performed on pre- and/or post-treatment material were compared to affinity data of the mutated receptor towards the inhibitor. Molecular modeling evidence was found to be consistent with sensitivity of mutated PDGFRA receptors to Imatinib. Thus, the {"}in vivo{"} evidence that these two mutations of PDGFRA are sensitive to Imatinib was confirmed by a multidimensional approach comprising {"}in silico{"} experiments that, in association to molecular and biochemical analyses, constitutes a powerful tool to predict Imatinib sensitivity, clinically beneficial in the treatment of these tumors with molecularly targeted therapies.",
keywords = "GIST, Imatinib-mesylate, PDGFRA, targeted therapy",
author = "Palma Dileo and Sabrina Pricl and Elena Tamborini and Tiziana Negri and Silvia Stacchiotti and Alessandro Gronchi and Paola Posocco and Erik Laurini and Paola Coco and Elena Fumagalli and Casali, {Paolo G.} and Silvana Pilotti",
year = "2011",
month = "2",
day = "15",
doi = "10.1002/ijc.25418",
language = "English",
volume = "128",
pages = "983--990",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations

T2 - An imaging, biochemical and molecular modeling study

AU - Dileo, Palma

AU - Pricl, Sabrina

AU - Tamborini, Elena

AU - Negri, Tiziana

AU - Stacchiotti, Silvia

AU - Gronchi, Alessandro

AU - Posocco, Paola

AU - Laurini, Erik

AU - Coco, Paola

AU - Fumagalli, Elena

AU - Casali, Paolo G.

AU - Pilotti, Silvana

PY - 2011/2/15

Y1 - 2011/2/15

N2 - Beside the well known "in vivo" and "in vitro" Imatinib resistant D842V mutation in PDGFRA receptor, very few are the information concerning the "in vivo" Imatinib activity with respect to the other PDGFRA mutations for which only "in vitro" data are available. Two patients carrying PDGFRA mutations in exons 18 (involving residues DIMH842-845) and 12 (V561D), respectively, were treated with Imatinib at a dose of 400 mg/day. According to Response Evaluation Criteria in Solid Tumors criteria, after a median treatment of 7 months both patients showed clinical partial response, and underwent surgery of the minimal residual disease. Tumor response was confirmed pathologically. In both patients, analyses of PDGFRA performed on pre- and/or post-treatment material were compared to affinity data of the mutated receptor towards the inhibitor. Molecular modeling evidence was found to be consistent with sensitivity of mutated PDGFRA receptors to Imatinib. Thus, the "in vivo" evidence that these two mutations of PDGFRA are sensitive to Imatinib was confirmed by a multidimensional approach comprising "in silico" experiments that, in association to molecular and biochemical analyses, constitutes a powerful tool to predict Imatinib sensitivity, clinically beneficial in the treatment of these tumors with molecularly targeted therapies.

AB - Beside the well known "in vivo" and "in vitro" Imatinib resistant D842V mutation in PDGFRA receptor, very few are the information concerning the "in vivo" Imatinib activity with respect to the other PDGFRA mutations for which only "in vitro" data are available. Two patients carrying PDGFRA mutations in exons 18 (involving residues DIMH842-845) and 12 (V561D), respectively, were treated with Imatinib at a dose of 400 mg/day. According to Response Evaluation Criteria in Solid Tumors criteria, after a median treatment of 7 months both patients showed clinical partial response, and underwent surgery of the minimal residual disease. Tumor response was confirmed pathologically. In both patients, analyses of PDGFRA performed on pre- and/or post-treatment material were compared to affinity data of the mutated receptor towards the inhibitor. Molecular modeling evidence was found to be consistent with sensitivity of mutated PDGFRA receptors to Imatinib. Thus, the "in vivo" evidence that these two mutations of PDGFRA are sensitive to Imatinib was confirmed by a multidimensional approach comprising "in silico" experiments that, in association to molecular and biochemical analyses, constitutes a powerful tool to predict Imatinib sensitivity, clinically beneficial in the treatment of these tumors with molecularly targeted therapies.

KW - GIST

KW - Imatinib-mesylate

KW - PDGFRA

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=78650597144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650597144&partnerID=8YFLogxK

U2 - 10.1002/ijc.25418

DO - 10.1002/ijc.25418

M3 - Article

C2 - 20473908

AN - SCOPUS:78650597144

VL - 128

SP - 983

EP - 990

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -